TNG712
Undisclosed
PreclinicalActive
Key Facts
About Tango Therapeutics
Tango Therapeutics is a clinical-stage biotech focused on discovering and developing precision oncology medicines based on synthetic lethality. The company has built a robust pipeline with multiple clinical-stage assets, including PRMT5 and CoREST inhibitors, targeting cancers with specific genetic alterations like MTAP deletion and STK11 mutations. Its integrated discovery platform combines CRISPR-based functional genomics with patient-derived data to systematically identify novel drug targets, positioning it at the forefront of next-generation cancer therapeutics.
View full company profileTherapeutic Areas
Other Undisclosed Drugs
| Drug | Company | Phase |
|---|---|---|
| Preclinical ISAC 1 | Bolt Biotherapeutics | Preclinical |
| Preclinical ISAC 2 | Bolt Biotherapeutics | Preclinical |
| ART12.11 | Artelo Biosciences | Preclinical |
| Novel Vaccines | MSD | Development |
| SLS-009 | Seelos Therapeutics | Discovery |
| Measovir®-based Prophylactic Vaccine (with Unither) | Oncovita | Research/Pre-clinical |
| Internal sdAb Discovery Program | NanoTag Biotechnologies | Discovery |
| Amgen Collaboration Program | Xeris Biopharma | Pre-clinical |
| NB-701 | Nerai Biosciences | Discovery |
| Undisclosed Therapeutic Program(s) | Bright Cell | Clinical Trial (Phase unspecified) |
| Biosimilars Pipeline | Intelligent Therapeutics | Pre-clinical/Development |
| Proprietary Therapeutic Pipeline | Excelsior Sciences | Discovery |